Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
Crescent Biopharma Inc (Pre-Reincorporation)
Research & Development
Crescent Biopharma Inc (Pre-Reincorporation)
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Crescent Biopharma Inc (Pre-Reincorporation)
NASDAQ:CBIO
|
Research & Development
-$14m
|
CAGR 3-Years
32%
|
CAGR 5-Years
21%
|
CAGR 10-Years
5%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$8.8B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Research & Development
-$5.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-12%
|
|
Crescent Biopharma Inc (Pre-Reincorporation)
Glance View
Crescent Biopharma Inc (Pre-Reincorporation) is a US-based company operating in Biotechnology industry. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. Crescent Biopharma Inc., formerly GlycoMimetics, Inc., is a biotechnology company. The firm is engaged in advancing novel precision-engineered molecules to advance care for patients with solid tumors. The Company’s lead program is CR-001, a tetravalent PD-1 x VEGF bispecific antibody in development for the treatment of solid tumors, and it is also advancing CR-002 and CR-003, antibody drug conjugates (ADCs) with topoisomerase inhibitor payloads for undisclosed targets. CR-002 and CR-003 are ADCs designed to deliver clinically active cytotoxic drugs known as topoisomerase inhibitors to tumor cells. Each of these programs has the potential to deliver therapeutics with clinical efficacy both as a monotherapy and in combination with CR-001 with significant potential across solid tumor indications.
See Also
What is Crescent Biopharma Inc (Pre-Reincorporation)'s Research & Development?
Research & Development
-14m
USD
Based on the financial report for Jun 30, 2025, Crescent Biopharma Inc (Pre-Reincorporation)'s Research & Development amounts to -14m USD.
What is Crescent Biopharma Inc (Pre-Reincorporation)'s Research & Development growth rate?
Research & Development CAGR 10Y
5%
Over the last year, the Research & Development growth was 39%. The average annual Research & Development growth rates for Crescent Biopharma Inc (Pre-Reincorporation) have been 32% over the past three years , 21% over the past five years , and 5% over the past ten years .
